Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Asco 2021 – Guardant shoots for the moon
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
Google gears up to launch its first medical device
But with Derm Assist available free, how will the company make money?
Aortic opportunity remains narrow for Abbott
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
